Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Meloxicam for Canine Osteoarthritis Pain: Efficacy, Safety, and 2025 Head-to-Head vs. Bedinvetmab
Meloxicam (COX-2 NSAID) equals bedinvetmab for canine OA efficacy in 2025 RCT (n=101), with more GI adverse events. Standard dose: 0.2 mg/kg loading the...
Read →Enflicoxib (Daxocox) for Canine Osteoarthritis: A Once-Weekly COX-2 Selective NSAID
Enflicoxib (Daxocox) is an EU-authorised, once-weekly COX-2 selective NSAID for canine osteoarthritis. This hub reviews its mechanism, 6-month field efficacy and safety (Salichs 2024), long-term durability, comparators, and clinical placement.
Read →Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence
Grapiprant (Galliprant) for canine osteoarthritis: EP4 receptor antagonism mechanism, the pivotal JVIM field study (48.1% vs 31.3% success), FDA/EMA approval, meloxicam and firocoxib comparators, RCVS-appraised evidence strength, and multimodal use in young dogs and cats.
Read →Librela (Bedinvetmab) in Dogs: Efficacy, Adverse Events & Monitoring
Librela (bedinvetmab) in dogs — side effects, the 2025 musculoskeletal/RPOA safety debate, efficacy vs meloxicam and grapiprant, contraindications, and monitoring. Cited for practitioners.
Read →